Sharon Barr
4Patents
2h-index
4Co-inventors
37Inventor score
Filing activity: Mar 13, 2007 → Sep 26, 2018
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7651687B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | Human Necessities | 22 | Active |
| US8114846B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | Human Necessities | 2 | Active |
| US11761963B2 | Biomarker signature for predicting tumor response to anti-CD200 therapy | Physics | 0 | Active |
| US8586546B2 | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors | Human Necessities | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.